Mechanisms of Seizure Genesis in Human Hypothalamic Hamartomas

人类下丘脑错构瘤癫痫发作的发生机制

基本信息

  • 批准号:
    7561641
  • 负责人:
  • 金额:
    $ 21.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-04-01 至 2011-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The hypothalamic hamartoma (HH) is a rare congenital human brain malformation associated with gelastic (or laughing) seizures that are difficult to diagnosis early in life and are notoriously refractory to medical therapy. Despite increasing clinical recognition of this condition, the mechanisms of epileptogenesis are largely unknown. Importantly, seizures have previously been shown to originate from the hamartoma itself. At the Barrow Neurological Institute, we have treated over 100 patients with this condition over the past several years, constituting the largest single-center series ever; we are currently the only multidisciplinary program for HH management in the United States, and the most active HH program in the world. Thus, we are uniquely positioned to study the mechanisms of epileptogenesis in HH. The major goal of the proposed studies is to determine the mechanisms of seizure genesis in surgically resected HH tissue using a combination of cellular electrophysiological, fluorescence imaging, immunocytochemical and gene expression techniques. Our preliminary data demonstrate that HH tissue contains two distinct populations of neurons; small HH neurons exhibit intrinsic pacemaker-like activity, whereas large HH neurons are quiescent. We have demonstrated that a subpopulation of large HH neurons depolarize when perfused with the GABAA-receptor agonist muscimol. Based on these intriguing findings, we hypothesize that such GABAA-receptor mediated depolarization may be a consequence of decreased expression of the cation-chloride co-transporter KCC2 (relative to its cousin, NKCC1), and that such responses may contribute to seizure genesis. Specifically, we hypothesize that muscimol will increase intracellular calcium levels, an effect that can be blocked by the NKCC1 antagonist bumetanide. Further, we hypothesize that HH tissue will demonstrate decreased expression of KCC2 relative to NKCC1 using immunocytochemical and single-cell RT-PCR expression techniques. Although HH itself is uncommon with an estimated prevalence of 1 in 50,000-100,000 it is perhaps the best human model for subcortical epilepsy, and one of the most intriguing models for understanding the consequences of catastrophic epilepsy in childhood. As such, a detailed scientific understanding of this disorder has major ramifications for expediting translational research focused on the developmental epilepsies. PUBLIC HEALTH RELEVANCE: Epilepsy is a common neurological disorder that afflicts more than 3 million people in the United States alone, and many newly diagnosed patients are infants and children. There is a substantial need to understand how epilepsy develops in the pediatric population in order to develop newer, more effective treatments. This research proposal, while focused on a rare brain tumor that causes uncontrolled seizures, may provide novel insights into the mechanisms of seizure propagation and progression.
描述(由申请人提供):下丘脑错构瘤(HH)是一种罕见的先天性人类大脑畸形,与弹性(或大笑)发作有关,在生命早期很难诊断,并且众所周知难以药物治疗。尽管越来越多的临床认识到这种情况,癫痫发生的机制在很大程度上是未知的。重要的是,癫痫发作已经被证明是由错构瘤本身引起的。在巴罗神经学研究所,在过去的几年里,我们已经治疗了100多名患有这种疾病的患者,构成了有史以来最大的单中心系列;我们目前是美国唯一的HH管理多学科项目,也是世界上最活跃的HH项目。因此,我们有独特的优势来研究HH的癫痫发生机制。所提出的研究的主要目的是利用细胞电生理、荧光成像、免疫细胞化学和基因表达技术的组合来确定手术切除的HH组织中癫痫发作的机制。我们的初步数据表明,HH组织包含两个不同的神经元群体;小的HH神经元表现出内在的类似起搏器的活动,而大的HH神经元是静止的。我们已经证明,当灌注gabaa受体激动剂muscimol时,大HH神经元亚群会去极化。基于这些有趣的发现,我们假设这种gabaa受体介导的去极化可能是阳离子-氯共转运体KCC2(相对于其表亲NKCC1)表达减少的结果,并且这种反应可能有助于癫痫发作的发生。具体来说,我们假设muscimol会增加细胞内钙水平,这一作用可以被NKCC1拮抗剂布美他胺阻断。此外,我们利用免疫细胞化学和单细胞RT-PCR表达技术推测HH组织中KCC2相对于NKCC1的表达会降低。虽然HH本身并不常见,估计患病率为5 -10万分之一,但它可能是皮质下癫痫的最佳人类模型,也是了解儿童灾难性癫痫后果的最有趣的模型之一。因此,对这种疾病的详细科学理解对于加快对发育性癫痫的转化研究具有重要的影响。公共卫生相关性:癫痫是一种常见的神经系统疾病,仅在美国就有300多万人患有该病,许多新诊断的患者是婴儿和儿童。为了开发更新、更有效的治疗方法,有必要了解癫痫在儿科人群中的发展情况。这项研究计划,虽然专注于一种罕见的脑肿瘤,导致不受控制的癫痫发作,可能提供新的见解,癫痫发作的传播和进展的机制。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
L-Type calcium channel blockade reduces network activity in human epileptic hypothalamic hamartoma tissue.
L 型钙通道阻断可降低人癫痫下丘脑错构瘤组织中的网络活动。
  • DOI:
    10.1111/j.1528-1167.2010.02942.x
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    5.6
  • 作者:
    Simeone,KristinaA;Sabesan,Shivkumar;Kim,DoYoung;Kerrigan,JohnF;Rho,JongM;Simeone,TimothyA
  • 通讯作者:
    Simeone,TimothyA
Bicarbonate contributes to GABAA receptor-mediated neuronal excitation in surgically resected human hypothalamic hamartomas.
  • DOI:
    10.1016/j.eplepsyres.2008.09.008
  • 发表时间:
    2009-01
  • 期刊:
  • 影响因子:
    2.2
  • 作者:
    Kim, Do-Young;Fenoglio, Kristina A.;Kerrigan, John F.;Rho, Jong M.
  • 通讯作者:
    Rho, Jong M.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jong Min Rho其他文献

Jong Min Rho的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jong Min Rho', 18)}}的其他基金

8th Global Symposium on Ketogenic Therapies
第八届全球生酮疗法研讨会
  • 批准号:
    10753748
  • 财政年份:
    2023
  • 资助金额:
    $ 21.49万
  • 项目类别:
Mechanisms of Seizure Genesis in Human Hypothalamic Hamartomas
人类下丘脑错构瘤癫痫发作的发生机制
  • 批准号:
    7428968
  • 财政年份:
    2008
  • 资助金额:
    $ 21.49万
  • 项目类别:
International Symposium on Dietary Therapies for Epilepsy and Other Neurological
癫痫及其他神经疾病饮食治疗国际研讨会
  • 批准号:
    7485255
  • 财政年份:
    2008
  • 资助金额:
    $ 21.49万
  • 项目类别:
GABAergic Inhibition and the Ketogenic Diet
GABA能抑制和生酮饮食
  • 批准号:
    7216408
  • 财政年份:
    2003
  • 资助金额:
    $ 21.49万
  • 项目类别:
GABAergic Inhibition and the Ketogenic Diet
GABA能抑制和生酮饮食
  • 批准号:
    7089078
  • 财政年份:
    2003
  • 资助金额:
    $ 21.49万
  • 项目类别:
GABAergic Inhibition and the Ketogenic Diet
GABA能抑制和生酮饮食
  • 批准号:
    6697494
  • 财政年份:
    2003
  • 资助金额:
    $ 21.49万
  • 项目类别:
GABAergic Inhibition and the Ketogenic Diet
GABA能抑制和生酮饮食
  • 批准号:
    6556580
  • 财政年份:
    2003
  • 资助金额:
    $ 21.49万
  • 项目类别:
GABAergic Inhibition and the Ketogenic Diet
GABA能抑制和生酮饮食
  • 批准号:
    6846232
  • 财政年份:
    2003
  • 资助金额:
    $ 21.49万
  • 项目类别:
POTASSIUM CHANNELS AND EPILEPTOGENESIS
钾通道与癫痫发生
  • 批准号:
    6393137
  • 财政年份:
    1997
  • 资助金额:
    $ 21.49万
  • 项目类别:
POTASSIUM CHANNELS AND EPILEPTOGENESIS
钾通道与癫痫发生
  • 批准号:
    2735506
  • 财政年份:
    1997
  • 资助金额:
    $ 21.49万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 21.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 21.49万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 21.49万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 21.49万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 21.49万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 21.49万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 21.49万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 21.49万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 21.49万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 21.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了